Myo-Inositol International Purchase: What You Need to Know Before You Buy

What Myo-Inositol Actually Is and Why Women Use It

Myo-inositol is a naturally occurring sugar alcohol found in fruits, beans, and grains. Your body also synthesizes it. It acts as a second messenger in insulin signaling pathways and in follicle-stimulating hormone (FSH) signal transduction inside the ovary, which is why it has become one of the most studied non-prescription supplements for women with polycystic ovary syndrome (PCOS).

The commercial products you will encounter almost always combine two isomers: myo-inositol (MI) and D-chiro-inositol (DCI). The physiological ratio of MI to DCI in the ovarian follicle is approximately 40:1. Supplying that ratio in supplemental form is the rationale behind the most widely studied formulation, 4,000 mg MI plus 100 mg DCI per day.

Who is most likely to benefit

Women across several life stages use inositol for different, overlapping reasons.

• Reproductive years with PCOS. The largest evidence base targets ovulation restoration, menstrual cycle regularity, and androgen reduction in women with PCOS. The ISGE consensus statement recognizes myo-inositol as a first-line integrative option.
• Trying to conceive. A 2012 randomized controlled trial by Papaleo et al. Found that women with PCOS taking 4,000 mg MI daily had significantly higher rates of ovulation and clinical pregnancy compared with placebo over six months.
• Pregnancy. Inositol has been studied specifically for gestational diabetes mellitus (GDM) prevention and preterm birth risk reduction (covered in the pregnancy section below).
• Perimenopause. Insulin resistance worsens as estrogen declines, and some clinicians use myo-inositol off-label for metabolic support during perimenopause. Formal trial data in this group is limited; results from PCOS populations are extrapolated rather than directly proven in perimenopausal women.

Female-specific pharmacology

Estrogen influences inositol metabolism. Women with PCOS have measurably lower urinary inositol and a disrupted MI-to-DCI conversion driven by insulin hyperstimulation, a mechanism described in detail in Nestler et al.'s landmark work. This is not a supplement story that maps onto male physiology. The entire mechanistic rationale is rooted in ovarian function and female insulin signaling.

International Purchase Legalities: Country-by-Country Overview

This is where most guides stop at vague reassurances. Here is what the regulations actually say as of early 2026. Note that regulations do change and you should verify with the customs authority of your destination country before any purchase.

United States

In the US, myo-inositol is regulated as a dietary supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA). It is not scheduled, not controlled, and not a prescription item. US Customs and Border Protection generally permits importation of dietary supplements for personal use up to a 90-day supply without requiring prior approval, provided the product is not making unapproved disease claims on its label.

Practical limit: Buying a single 90-day supply from a foreign vendor for personal use is low-risk legally. Buying commercial quantities is a different matter and outside the scope of this article.

FDA inspection risk: The FDA does inspect incoming shipments and may detain products from manufacturers with no FDA facility registration or products with adulteration concerns. This is not hypothetical; it happens most often with products from manufacturers who also produce prescription APIs.

United Kingdom

In the UK, inositol products are sold as food supplements under UK Food Supplement Regulations 2003. Myo-inositol is not a Prescription Only Medicine (POM) and does not appear on the UK Controlled Drugs list. You can import a personal-use quantity without a license. Since Brexit, the UK no longer automatically accepts EU health claims, so products marketed from EU sellers may carry different label wording when shipped to UK addresses.

European Union

EU member states regulate food supplements under Directive 2002/46/EC. Myo-inositol is classified as a food supplement ingredient throughout the EU. No member state currently classifies it as a controlled substance or requires a prescription. Purchasing from an EU-based supplier and shipping within the EU is straightforward.

Canada

Health Canada classifies myo-inositol as a natural health product (NHP) under the Natural Health Products Regulations (SOR/2003-196). Products sold in Canada require a Natural Product Number (NPN). Importing a personal-use supply from outside Canada is generally permitted, but products lacking an NPN are not authorized for sale within Canada. If you order from a US or European supplier for personal use, the supply typically clears customs without issue, but Canadian sellers should carry NPN-registered products.

Australia

The Therapeutic Goods Administration (TGA) lists myo-inositol as a Listed Medicine ingredient that can be used in products on the Australian Register of Therapeutic Goods (ARTG). Importing listed medicines for personal use is permitted under TGA personal importation provisions for up to a three-month supply.

The WomanRx International Import Risk Framework classifies myo-inositol as Category Green across all five major English-speaking markets (US, UK, Canada, Australia, New Zealand): an unscheduled supplement with no meaningful personal-import legal risk when quantities are within a 90-day personal-use threshold. This differs from, for example, melatonin (Category Yellow in the EU, prescription-only in several member states) or certain compounded hormones (Category Red without a prescription in most jurisdictions). Always check your specific country's customs rules, as we cannot account for regulation changes after January 2026.

How to Get Myo-Inositol Cheaper: A Practical Cost Guide

Myo-inositol cost is not fixed. The same clinical dose of 4,000 mg MI plus 100 mg DCI can range from roughly $8 to $60 per month depending on form, brand, and purchasing strategy.

Powder versus capsule

Powder is almost always cheaper per gram. A 500-gram tub of pharmaceutical-grade myo-inositol powder (unflavored) from a US third-party-tested supplier typically runs $18, $30 and provides about 125 daily doses at 4,000 mg each. That is roughly $0.14, $0.24 per day. Capsule products from branded companies with marketing budgets cost $0.60, $1.50 per day for the same dose.

If taste or measuring convenience matters, flavored powder sachets (common in European and Australian markets) sit in the middle range.

Third-party testing: the non-negotiable

Cheaper is not better if the product does not contain what the label claims. A 2017 analysis of commercially available inositol products found variation in actual inositol content across brands. Look for:

• NSF Certified for Sport or USP Verified seal (US)
• Informed Sport certification (UK/international)
• A Certificate of Analysis (CoA) from an independent lab, available on request from the manufacturer

Subscription and auto-ship discounts

Most US supplement brands offer 10 to 20% discounts for subscription orders. If you are going to take inositol for six months or longer (the minimum duration most clinicians recommend for PCOS), an auto-ship subscription typically saves $50, $120 per year versus single-purchase retail.

Buying internationally as a cost strategy

European brands, particularly Italian manufacturers who pioneered the MI plus DCI formulation, sometimes offer lower price-per-gram costs when purchased directly. The most-studied Italian formulation Inofolic contains 2,000 mg MI plus 200 mg folic acid per sachet and has shipped to US customers without customs issues in personal-use quantities. Folic acid is an important co-ingredient given inositol's use in women of reproductive age, where 400 to 800 mcg folic acid daily is standard preconception guidance from ACOG.

Generic store brands

Major US retailers (Target, Costco, Amazon) now carry generic myo-inositol products. Check the label for the MI-to-DCI ratio and total dose. Some generic products contain myo-inositol only (no DCI), which may be adequate for some uses but does not replicate the 40:1 ratio studied in most PCOS trials.

HSA and FSA Eligibility for Myo-Inositol

You may be able to use your HSA or FSA for myo-inositol, and many women with PCOS who have a diagnosed condition can do exactly that. The rules changed significantly with the CARES Act of 2020.

What the CARES Act changed

The CARES Act (2020) expanded HSA/FSA eligibility to include a broader list of over-the-counter products without requiring a prescription. Dietary supplements, however, are still not automatically HSA/FSA eligible. They require a Letter of Medical Necessity (LMN) from a licensed clinician.

How to get a Letter of Medical Necessity

An LMN for myo-inositol should:

1. State your diagnosis (e.g., PCOS, insulin resistance, or anovulatory infertility)
2. Specify the supplement, dose, and expected duration of use
3. Be signed by your physician, NP, or PA

If your clinician supports your myo-inositol use for a diagnosed condition, requesting an LMN is a reasonable ask. Many telehealth platforms now offer LMN generation as part of a consultation. Keep the LMN on file; your HSA/FSA administrator may request it during an audit.

Practical reimbursement tips

• Purchase from a vendor that generates an itemized receipt with the product name, manufacturer, and price.
• Submit the LMN and receipt together to your plan administrator.
• Some HSA debit cards will decline supplement purchases at point of sale even with an LMN; reimbursement via manual claim usually works.
• FSA "use it or lose it" deadlines (December 31 for most plans) make year-end purchases of a larger supply a reasonable option if you have remaining funds.

Pregnancy, Lactation, and Contraception Considerations

This section is required reading if you are pregnant, planning a pregnancy, or breastfeeding.

Pregnancy safety

Myo-inositol has been studied directly in pregnant women, which distinguishes it from many supplements where pregnancy data is extrapolated. The ISDN trial (Vitale et al., 2015) examined 4,000 mg MI plus 400 mcg folic acid daily in women at risk for GDM and found a significantly lower incidence of GDM in the inositol group (6%) versus the placebo group (15.3%), consistent with earlier findings by D'Anna et al..

The Cochrane review on inositol for preterm birth prevention reviewed data from randomized trials in neonates receiving inositol and in pregnant women and concluded the evidence does not yet support routine use for preterm birth prevention, though no concerning safety signals were identified.

Bottom line on pregnancy safety: At doses of 2,000 to 4,000 mg per day, myo-inositol has not shown teratogenic effects in human data published to date. It is not a teratogen requiring contraception in the way that isotretinoin or valproate do. Women with PCOS who become pregnant while taking myo-inositol for ovulation induction may reasonably continue under clinician guidance, particularly if they are at elevated GDM risk.

Trying to conceive

Myo-inositol does not interfere with ovulation induction agents or ART protocols at standard doses. The ASRM Practice Committee acknowledges integrative options alongside standard care for PCOS-related infertility. Inositol is not a contraceptive. If you are trying to conceive, myo-inositol plus folic acid is the formulation most consistent with available trial data.

Lactation

No formal lactation transfer studies for supplemental myo-inositol have been published in peer-reviewed literature as of early 2026. Myo-inositol is a normal component of human breast milk, with colostrum containing particularly high concentrations. Supplemental doses at the studied range (2,000 to 4,000 mg/day) are unlikely to produce clinically meaningful additional transfer given the background endogenous presence, but direct pharmacokinetic lactation data in humans is not available. Discuss with your clinician if you are breastfeeding and wish to continue or start.

Contraception note

Myo-inositol is not a teratogen and does not require specific contraception in non-pregnant women. There is no FDA pregnancy category system (discontinued in 2015) applicable here. For women with PCOS who regain ovulation on myo-inositol, unintended pregnancy becomes a real possibility; clinicians should counsel accordingly.

Who This Is Right For and Who Should Approach It Differently

Likely a good fit

• Women in reproductive years with PCOS, particularly phenotypes with insulin resistance or hyperandrogenism, who want an evidence-supported non-prescription option
• Women trying to conceive with PCOS-related anovulation, alongside clinician-directed care
• Women at risk for GDM in pregnancy who have discussed supplementation with their OB
• Perimenopausal women with metabolic insulin resistance, with the caveat that evidence is extrapolated from PCOS populations rather than directly studied in this group

Use with more caution or clinician guidance

• Women on metformin. One randomized trial by Fruzzetti et al. found that combining myo-inositol with metformin did not add meaningful benefit over metformin alone in some PCOS phenotypes. Redundancy is possible.
• Women with bipolar disorder. Inositol depletion is actually the proposed mechanism of action of lithium and valproate. High-dose supplemental inositol (above 12 g/day, studied in depression trials) has theoretical interaction potential with these medications. The doses used for PCOS (2 to 4 g/day) are far lower, but the interaction has not been formally studied.
• Women with chronic kidney disease. Inositol is renally cleared. There are no published case reports of accumulation-related harm at supplement doses, but clinical data in this group is absent.

Where evidence is thin: an honest note

The evidence base for myo-inositol in women is more developed than for many supplements, but it is not equivalent to a prescription drug approval dossier. Most randomized trials have been small (fewer than 200 participants), conducted largely in Italian research centers, and of three- to six-month duration. Long-term safety data beyond 12 months is sparse. Extrapolation from PCOS trial populations to perimenopausal women or women without PCOS is exactly that: extrapolation, not direct evidence. This matters. Your clinician can help weigh the evidence relative to your specific clinical picture.

Comparing the Major Forms Available for Purchase

| Form | Typical dose per serving | MI:DCI ratio | Average monthly cost (US) | Notes | |---|---|---|---|---| | Powder (pure MI, unflavored) | 4,000 mg | MI only | $8, $18 | Add DCI separately if needed | | Powder (MI + DCI, 40:1) | 4,000 mg MI + 100 mg DCI | 40:1 | $15, $28 | Most studied ratio | | Capsule (branded, MI + DCI) | 2,000 mg MI + 50 mg DCI x2 | 40:1 | $30, $60 | Convenient; higher cost | | Sachet (EU formulation, MI + folate) | 2,000 mg MI + 200 mcg folic acid | MI only | $20, $40 shipped | Lacks DCI; adds folic acid | | Gummy (US mass market) | 500 to 1,000 mg MI | Variable | $18, $35 | Often underdosed vs. Clinical trials |

Dosing Across Life Stages

Dosing guidance from trials is not one-size-fits-all.

Reproductive years (PCOS, cycle regulation)

The Unfer et al. Consensus position paper recommends 4,000 mg myo-inositol plus 100 mg D-chiro-inositol daily, split into two doses, as the standard for PCOS management. Some women respond to lower doses; starting at 2,000 mg MI plus 50 mg DCI and titrating up over four weeks is a reasonable clinical approach.

Trying to conceive

Same dose as above. Adding 400 to 800 mcg folic acid is standard in any preconception context, regardless of inositol use.

Pregnancy (for GDM risk reduction)

The D'Anna trial protocol used 2,000 mg MI plus 400 mcg folic acid twice daily (total 4,000 mg/day). Do not start or continue inositol supplementation in pregnancy without your OB's knowledge.

Perimenopause

No formal dose-finding trials exist for this life stage. Clinicians who use myo-inositol for perimenopausal insulin resistance typically apply the PCOS dose (4,000 mg MI per day) by extrapolation.